# Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/real-world-efficacy-of-glecaprevir-plus-pibrentasvir-for-chronic-hepatitis-c/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Hiroshima Liver Study Group,Mitsutaka Osawa,Michio Imamura,Yuji Teraoka,Takuro Uchida,Kei Morio,Hatsue Fujino,Takashi Nakahara,Atsushi Ono,Eisuke Murakami,Tomokazu Kawaoka,Daiki Miki,Masataka Tsuge,Akira Hiramatsu,Hiroshi Aikata,C. Nelson Hayes,Kazuaki Chayama |
| Citations | 45 |
| DOI | 10.1007/s00535-018-1520-9 |
| Fields | Medicine,Pharmacology, Toxicology and Pharmaceutics |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2896376232 |
| PMID | 30334096 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Takuro Uchida](https://scholariq.org/researchers/takuro-uchida/)

## Paper primary topic

- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)

## Paper topics

- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)
- [Drug-Induced Hepatotoxicity and Protection](https://scholariq.org/topics/drug-induced-hepatotoxicity-and-protection/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.